RAC 11.1% $1.37 race oncology ltd

Ann: Zantrene data published in Cancer Research Journal, page-20

  1. 607 Posts.
    lightbulb Created with Sketch. 276
    Hi @Bran, thanks for posting here.
    I have a dumb question to ask, if you or anyone else would be kind enough to answer for me.

    My partner's brother was diagnosed with bowel cancer last month. He has had an operation to remove
    a 20cm section of his bowel. Scans [I'm not sure which] done before the operation gave indications
    that the cancer had not spread beyond the bowel, however, the surgeon removed several lymph nodes
    [26, I think] of which 1 has shown traces of cancer. He is now advised to undergo chemo treatment.

    My question: Is the cancer in his lymph node still considered bowel cancer, and if this cancer spreads
    through the lymphatic network [or elsewhere] is it still bowel cancer, and potentially treated with
    the 5-FU [flourouracil] as the chemo drug?

    It seems, from our announcement today, that Zantrene in combination with 5-FU, via FTO inhibition
    can potentially help colorectal cancer patients. Zantrene, as we know, is building a long list of
    cancers that are more treatable through this FTO inhibition.

    But, essentially, just asking, is colorectal cancer still colorectal cancer if it spreads outside the bowel,
    and is it generally treated with the "cornerstone" drug 5-FU?

    I haven't mentioned anything regarding this to my brother in law yet, as I don't want to send him down
    rabbit holes needlessly, on crazy advice from me.

    Thanks in advance. Nice to see a bit of a bump up today. Apologies for the long winded question.

 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.